VIRTUAL LEGAL ROUNDTABLE 2019 EFS MASTER CLINICAL TRIAL AGREEMENT - - PowerPoint PPT Presentation

VIRTUAL LEGAL ROUNDTABLE – 2019 EFS MASTER CLINICAL TRIAL AGREEMENT

Liliana Rincon-Gonzalez, PhD Program Director, Clinical Science Medical Device Innovation Consortium Jaime Walkowiak, JD

Chief Operating Officer, Baylor Scott & White Research Institute SVP, Baylor Scott & White Health

2

Objectives

• Provide a brief recap of 2018 Legal Roundtable and current initiative -

2019 Virtual Legal Roundtable.

• Provide a overview of the feedback received during current MCTA

review

• Discuss the substantive changes to the MCTA
• Elaborate on next steps to finalization of MCTA, Version 2

RECAP OF 2018 ROUNDTABLE AND PILOT USE OF MCTA

3

4

EFS – Contracting

Development of EFS MCTA – Version 1

MDIC Working Group Language Libraries

Conception

• f Legal

Roundtable Legal Roundtable

Reconciliation and Development

• f MCTA and

supplements

Distribution and use of MCTA template

5

EFS – Contracting

Conception of Legal Roundtable

• Goal - Develop an EFS-specific Master Clinical Trial Agreement (MCTA) to facilitate

efficiencies in the EFS contracting process which provides:

• balance between site and sponsor concerns, serving as a starting point for contract negotiations with

a priori agreement of 90% or greater, and

• allowing both parties to focus remaining legal resources on the remaining 10% (or less) of the EFS

MCTA requiring negotiation

• BSWRI took the lead on drafting a MCTA template using the provisions from the Language

Library developed by MDIC Working Group

• Draft MCTA circulated for review to the Legal Roundtable participants prior to the meeting
• Legal Roundtable was hosted by Baylor Scott & White Research Institute (BSWRI) on

February 8-9, 2018.

6

EFS – Contracting

2018 LEGAL ROUNTABLE AGENDA

The roundtable agenda focused on frequent key choke points in EFS contract negotiations:

• Indemnification
• Subject Injury
• Intellectual Property
• Third Party Payer
• Confidentiality
• Publication
• Audit

7

EFS – Contracting

Post Roundtable Discussion - Reconciliation and Development of MCTA and Industry and Sponsor-specific supplements

• Second review of the MCTA draft resulted in better understanding of organization's

variances from the template and led roundtable participants to the conclusion that MCTA alone would not resolve all concerns and that supplemental information would be necessary

• Written summaries of variances along with narrative explanation serve as a

supplement to the MCTA that equips people to efficiently make decisions on which institutions and sponsors to approach – reduces timeline to establish - eliminates meaningless negotiations

• Explore use of MCTA by a broader audience
• Obtain additional feedback received from 2018 Legal Roundtable

participants as well as new participants.

• Discuss pertinent items during today’s webinar
• Finalize, distribute, and publish, EFS CTA, Version 2

8

Current Initiative

2019 Virtual Legal Roundtable

EFS MCTA REVIEW – VERSION 2

9

• Conceptually minor edits
• Typo correction / reformatting of select provisions
• Clarifying language
• Proposed Substantive Edits
• Section 9 - Study Device
• Section 10 - Disclaimer
• Section 11.5 - Record Retention
• Section 15.3 - Inventions
• Section 16.1 – Confidentiality
• Section 20.3 – Reimbursement of Medical Expenses
• Any proposed changes that have not been incorporated, but required per

institution/company requirements should be added to the Institution/Company Specific Terms document.

10

EFS MCTA Version 2 Review

11

Proposed Modifications

Section 9 – Study Device

12

Proposed Modifications

Section 10 - Disclaimer

13

Proposed Modifications

Section 11.5 – Record Retention

Proposed Modifications

Section 15.3 - Inventions

15

Proposed Modifications

Section 16.1 – Exceptions to Confidentiality

16

Proposed Modifications

Section 20.3 – Reimbursement for Medical Expenses

• Feedback received from today’s webinar will be considered along

with the redlines/comment received previously via email.

• Typed comments from today’s webinar will be retained and analyzed

during the finalization of the Version 2 template.

• Updated copies of the Version 2 template will be distributed to all

participants once all feedback evaluated and any further edits have been made.

• We are evaluating multiple means to communicate to all participants

and obtain feedback on this work including in-person meetings, additional webinars, seminars, or other means.

17

EFS MCTA, Version 2 - Closing

Jaime Walkowiak

Chief Operating Officer Jaime.Walkowiak@BSWHealth.org

Liliana Rincon-Gonzalez Program Director, Clinical Science lrincon-gonzalez@mdic.org Pamela Goldberg President and CEO pgoldberg@mdic.org @MDIConline www.mdic.org 202-828-1600